Rare Disease Drug Market
Global Rare Disease Drug Market Size, Share & Trends Analysis Report By Drug Type (Biologics and Non-Biologics), and By Therapeutics Area (Cancer, Blood-related Disorders, Central Nervous System, Respiratory Disorders, Cardiovascular Disorders, and Others ) Forecast Period (2022-2028) Update Available - Forecast 2024-2030
The global rare disease drug market is anticipated to grow at a significant CAGR of 11.4% during the forecast period. The rising prevalence of rare diseases and their implications for healthcare spending have boosted demand for specialized treatments, leading to growth in the rare disease drug market. In addition, as product development continues, new technologies for diagnosing uncommon genetic illnesses are becoming more available which is supporting the growth of the market. Furthermore, favorable government policies aimed at raising awareness about the treatment of rare diseases are leading to an increase in the use of effective medicines for uncommon disorders. However, limited understanding of pathology and progression is acting as a restraining factor to the growth of the market.
Impact of COVID-19 Pandemic on Global Rare Disease Drug Market
The COVID-19 pandemic had a substantial impact on the market for rare disease drug market. People with rare disorders are particularly affected as global healthcare services are diverted to focus on COVID-19. In addition to the higher risk of serious disease for many patients due to weakened immune systems, these patients and the manufacturers of their medications face problems such as guaranteeing patient access to therapy, research failures, and supply concerns. Check-ups and frequent supportive care visits were being disrupted, due to which the momentum of ongoing care was affected and losing the critical support network for patient outcomes and experience. Additionally, due to the lockdown treatment of patients was affected. For instance, in 2021, according to the Eurordis International Survey, patients with rare diseases had a worse experience than patients with chronic diseases as a result of the COVID-19 pandemic. 60% of the participants in the study had their care interrupted, and 80% had cancelled or rescheduled their sessions.
Segmental Outlook
The global rare disease drug market is segmented based on drug type, and therapeutic area. Based on the drug type, the market is sub-segmented into biologics and non-biologics. Based on the therapeutic area, the market is sub-segmented into cancer, blood-related disorders, central nervous system, respiratory disorders, cardiovascular disorders, and others (musculoskeletal disorders).
Global Rare Disease Drug Market Share by Therapeutic Area, 2021 (%)
The Cancer Segment Holds the Prominent Market Share in the Global Rare Disease Drug Market
The cancer segment holds a significant share in the rare disease drug market due to the existence of multiple oncology treatments in product development pipelines, and a substantial number of rare disease drugs devoted to cancer treatment. Additionally, the increasing prevalence of rare cancer disorders is acting as another factor that is impacting the growth of the market. For instance, in 2019, according to the national cancer institute, rare cancers impact around 40,000 persons in the US each year.
Regional Outlooks
The global rare disease drug market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East & Africa, and Latin America). Among the regions, the Asia Pacific is anticipated to hold a significant share in the market followed by North America, and then Europe.
Global Rare Disease Drug Market Growth, by Region 2022-2028
The Asia-Pacific Region Expected to Hold Considerable Share in the Global Rare Disease Drug Market
The Asia-Pacific region holds the major share and is anticipated to grow significantly during the forecast period in the rare disease drug market. Due to rising healthcare spending and growing awareness of rare diseases, the market in the Asia Pacific is likely to develop significantly. The region has a large patient population combined with a high rate of adoption of sophisticated rare disease medicines. To aid the discovery of innovative pharmaceuticals for the treatment of rare diseases, countries such as Japan have established support networks and special regulatory authorities. Grants-in-aid for research initiatives, pricing control rules negotiated between the Japanese National Health Insurance (NIH) and pharmaceutical corporations, and medical reimbursement for 56 diseases are all part of Japan's support system.
Market Players Outlook
The major companies serving the global rare disease drug market include Bristol-Myers Squibb Co., F.Hoffmann-La Roche Ltd., Amgen Inc., Alexion Pharmaceuticals, Inc., Novartis AG, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, In October 2019, Bristol Myers Squibb had acquired Celgene for around $74 billion which is a provider of orphan drugs.
In February 2019, Spark Therapeutics biotech which focuses on gene therapy for rare and hereditary diseases had been acquired by F. Hoffmann-La Roche for nearly $4.8 billion.
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global rare disease drug market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on the Global Rare Disease Drug Market
• Recovery Scenario of Global Rare Disease Drug Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. BY Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Alexion Pharmaceuticals, Inc.
3.1.1.1. Overview
3.1.1.2. Financial Analysis
3.1.1.3. SWOT Analysis
3.1.1.4. Recent Developments
3.1.2. Amgen Inc.
3.1.2.1. Overview
3.1.2.2. Financial Analysis
3.1.2.3. SWOT Analysis
3.1.2.4. Recent Developments
3.1.3. Bristol-Myers Squibb Co.
3.1.3.1. Overview
3.1.3.2. Financial Analysis
3.1.3.3. SWOT Analysis
3.1.3.4. Recent Developments
3.1.4. F. Hoffmann-La Roche Ltd
3.1.4.1. Overview
3.1.4.2. Financial Analysis
3.1.4.3. SWOT Analysis
3.1.4.4. Recent Developments
3.1.5. Novartis AG
3.1.5.1. Overview
3.1.5.2. Financial Analysis
3.1.5.3. SWOT Analysis
3.1.5.4. Recent Developments
3.2. Key Strategy Analysis
3.3. Impact of COVID-19 on Key Players
4. Market Segmentation
4.1. Global Rare Disease Drug Market by Drug Type
4.1.1. Biologics
4.1.2. Non-biologics
4.2. Global Rare Disease Drug Market by Therapeutic Area
4.2.1. Cancer
4.2.2. Blood-Related Disorders
4.2.3. Central Nervous System (CNS)
4.2.4. Respiratory Disorders
4.2.5. Cardiovascular Disorders
4.2.6. Others (Musculoskeletal Disorders)
5. Regional Analysis
5.1. North America
5.1.1. US
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. Abbott
6.2. Agios Pharmaceuticals, Inc.
6.3. AstraZeneca
6.4. Bayer AG
6.5. Chiasma, Inc.
6.6. DAIICHI SANKYO CO. LTD.
6.7. Eli Lilly and Co.
6.8. Genelux Corp.
6.9. GlaxoSmithKline plc.
6.10. Merck & Co., Inc.
6.11. Novo Nordisk A/S
6.12. Pfizer Inc.
1. GLOBAL RARE DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2021-2028 ($ MILLION)
2. GLOBAL BIOLOGICS RARE DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL NON-BIOLOGICS RARE DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL RARE DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY THERAPEUTIC AREA, 2021-2028 ($ MILLION)
5. GLOBAL CANCER RARE DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6. GLOBAL BLOOD-RELATED DISORDERS RARE DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
7. GLOBAL CENTRAL NERVOUS SYSTEM (CNS) DISORDERS RARE DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
8. GLOBAL RESPIRATORY DISORDERS RARE DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
9. GLOBAL CARDIOVASCULAR DISORDERS RARE DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
10. GLOBAL OTHERS RARE DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
11. GLOBAL RARE DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
12. NORTH AMERICAN RARE DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
13. NORTH AMERICAN RARE DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2021-2028 ($ MILLION)
14. NORTH AMERICAN RARE DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY THERAPEUTIC AREA, 2021-2028 ($ MILLION)
15. EUROPEAN RARE DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
16. EUROPEAN RARE DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2021-2028 ($ MILLION)
17. EUROPEAN RARE DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY THERAPEUTIC AREA, 2021-2028 ($ MILLION)
18. ASIA-PACIFIC RARE DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
19. ASIA-PACIFIC RARE DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2021-2028 ($ MILLION)
20. ASIA-PACIFIC RARE DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY THERAPEUTIC AREA, 2021-2028 ($ MILLION)
21. REST OF THE WORLD RARE DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
22. REST OF THE WORLD RARE DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2021-2028 ($ MILLION)
23. REST OF THE WORLD RARE DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY THERAPEUTIC AREA, 2021-2028 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL RARE DISEASE DRUG MARKET, 2021-2028 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL RARE DISEASE DRUG MARKET BY SEGMENT, 2021-2028 ($ MILLION)
3. RECOVERY OF GLOBAL RARE DISEASE DRUG MARKET, 2022-2028 (%)
4. GLOBAL RARE DISEASE DRUG MARKET SHARE BY DRUG TYPE, 2021 VS 2028 (%)
5. GLOBAL BIOLOGICS RARE DISEASE DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
6. GLOBAL NON-BIOLOGICS RARE DISEASE DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
7. GLOBAL RARE DISEASE DRUG MARKET SHARE BY THERAPEUTIC AREA, 2021 VS 2028 (%)
8. GLOBAL CANCER RARE DISEASE DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
9. GLOBAL BLOOD-RELATED DISORDER RARE DISEASE DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
10. GLOBAL CENTRAL NERVOUS SYSTEM (CNS) RARE DISEASE DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
11. GLOBAL RESPIRATORY DISORDERS RARE DISEASE DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
12. GLOBAL CARDIOVASCULAR DISORDERS RARE DISEASE DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
13. GLOBAL OTHERS RARE DISEASE DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
14. GLOBAL RARE DISEASE DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
15. US RARE DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
16. CANADA RARE DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
17. UK RARE DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
18. FRANCE RARE DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
19. GERMANY RARE DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
20. ITALY RARE DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
21. SPAIN RARE DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
22. REST OF EUROPE RARE DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
23. INDIA RARE DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
24. CHINA RARE DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
25. JAPAN RARE DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
26. SOUTH KOREA RARE DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
27. REST OF ASIA-PACIFIC RARE DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
28. REST OF THE WORLD RARE DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
